Celldex Therapeutics (CLDX) Return on Sales (2016 - 2025)
Celldex Therapeutics (CLDX) has 16 years of Return on Sales data on record, last reported at 672.05% in Q4 2025.
- For Q4 2025, Return on Sales fell 63197.0% year-over-year to 672.05%; the TTM value through Dec 2025 reached 167.48%, down 14499.0%, while the annual FY2025 figure was 167.48%, 14499.0% down from the prior year.
- Return on Sales reached 672.05% in Q4 2025 per CLDX's latest filing, down from 67044.0% in the prior quarter.
- Across five years, Return on Sales topped out at 67044.0% in Q3 2025 and bottomed at 672.05% in Q4 2025.
- Average Return on Sales over 5 years is 3254.96%, with a median of 50.24% recorded in 2021.
- The widest YoY moves for Return on Sales: up 6705720bps in 2025, down -63197bps in 2025.
- A 5-year view of Return on Sales shows it stood at 60.4% in 2021, then surged by 73bps to 16.42% in 2022, then surged by 36bps to 10.48% in 2023, then tumbled by -282bps to 40.08% in 2024, then crashed by -1577bps to 672.05% in 2025.
- Per Business Quant database, its latest 3 readings for Return on Sales were 672.05% in Q4 2025, 67044.0% in Q3 2025, and 77.53% in Q2 2025.